Meta‐analysis: oral bisphosphonates and the risk of oesophageal cancer

@article{Andrici2012MetaanalysisOB,
  title={Meta‐analysis: oral bisphosphonates and the risk of oesophageal cancer},
  author={Juliana Andrici and Martin Tio and Guy D. Eslick},
  journal={Alimentary Pharmacology \& Therapeutics},
  year={2012},
  volume={36}
}
Bisphoshonates, which are used in the treatment and prevention of osteoporosis, have recently been implicated in the development of oesophageal cancer; however, studies report conflicting data. 
Bisphosphonate use and the risk of endometrial cancer: a meta‐analysis of observational studies
The association of bisphosphonate use and the risk of endometrial cancer is still unclear. No meta‐analysis was conducted to review the evidence concerning this topic.
Oral Bisphosphonates and Risk of Cancer
TLDR
The possibility of an association with cancer development, especially the potential for a protective effect is intriguing, and the wide use of bisphosphonates in the treatment and prevention of osteoporosis and patients with cancer metastases to bone or multiple myeloma is intriguing. Expand
Oral bisphosphonates and risk of esophageal cancer : a meta-analysis
Objectives: The association between oral bisphosphonate (BP) intake and esophageal cancer risk has been investigated in several recent studies with conflicting results. Methods: We conducted aExpand
Anti-resorptive Therapies
TLDR
This chapter discusses some of the most commonly used anti-resorptive agents, in addition to calcium and vitamin D supplementation which are often used as adjunctive therapy. Expand
The Carcinogenicity of Alendronate in Patients with Osteoporosis: Evidence from Cohort Studies
TLDR
Alendronate therapy may be associated with a high risk of lung cancer, may with an excess risk of liver cancer, a low risk of colorectal and no related risk of other cancers. Expand
Bisphosphonates and evidence for association with esophageal and gastric cancer: a systematic review and meta-analysis
TLDR
A systematic review and meta-analysis of observational studies and sensitivity analysis of alendronate found no compelling evidence for a significantly raised risk of esophageal cancer or gastric cancer in male and female patients prescribed bisphosphonates. Expand
Bisphosphonates and risk of cancers: a systematic review and meta-analysis
TLDR
Bisphosphonates are significantly associated with risk reduction of colorectal, breast and endometrial cancer, especially nitrogen-containing bisph phosphonates, and large prospective cohort studies are needed to find the causal association between bisph phosphate and risk of cancers. Expand
Risk reduction of endometrial and ovarian cancer after bisphosphonates use: A meta-analysis.
TLDR
This meta-analysis suggests that the use of bisphosphonates is associated with a reduction in the risk of endometrial cancer but not ovarian cancer. Expand
Bisphosphonates and risk of lung cancer
TLDR
This is the most detailed meta-analysis on this topic and there was no significant association between the use of BPs and lung cancer, however, exposure to alendronate may increase the risk of lung cancer. Expand
Epidemiology and Risk Factors for Esophageal Cancer
The epidemiology of esophageal cancer has radically changed in the last 50 years in the Western world. Changes in the predominant type of squamous cell carcinoma to adenocarcinoma, disparitiesExpand
...
1
2
3
4
...

References

SHOWING 1-10 OF 43 REFERENCES
Occurrence of Gastrointestinal Cancer in Users of Bisphosphonates and Other Antiresorptive Drugs Against Osteoporosis
TLDR
The association between bisphosphonate use and risk of gastrointestinal (GI) cancers in a nationwide retrospective cohort from Denmark may not be causal as no dose–response or time relationship was present. Expand
Reports of esophageal cancer with oral bisphosphonate use.
  • D. Wysowski
  • Medicine
  • The New England journal of medicine
  • 2009
To the Editor: Between the time of the initial marketing of alendronate in October 1995 through mid-May 2008, the Food and Drug Administration (FDA) received reports of 23 patients in the UnitedExpand
Oral Bisphosphonates and Risk of Esophageal Cancer: A Dose-Intensity Analysis in a Nationwide Population
TLDR
The data suggest that bisphosphonates are not likely risk factors for esophageal cancer in Taiwan, and there is no evidence of an association between bisph phosphonate use and esophagal cancer risk from Asian perspective. Expand
ESOPHAGITIS ASSOCIATED WITH THE USE OF ALENDRONATE
A BSTRACT Background Alendronate, an aminobisphosphonate and a selective inhibitor of osteoclast-mediated bone resorption, is used to treat osteoporosis in postmenopausal women and Paget’s disease ofExpand
Exposure to oral bisphosphonates and risk of cancer
TLDR
Although reductions in breast and colorectal cancer incidence were observed in bisphosphonate users it is unclear, particularly for breast cancer, to what extent confounding by low bone density may explain the association. Expand
Oral Bisphosphonate Prescriptions and the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus
TLDR
In patients with BE, oral bisphosphonates were not associated with an increased risk of EAC, and the incidence density ratio was 0.92 (95% CI, 0.21–4.15). Expand
Oral alendronate use and risk of cancer in postmenopausal women with osteoporosis: A nationwide study
  • C. Chiang, Chin-Chou Huang, +6 authors H. Leu
  • Medicine
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2012
TLDR
Alendronate use was not associated with increased risk of cancer development in women with osteoporosis, and a Cox proportional‐hazard model, adjusted for confounding factors, was used to evaluate the association. Expand
Exposure to bisphosphonates and risk of cancer: a protocol for nested case–control studies using the QResearch primary care database
TLDR
This study will investigate the association of bisphosphonates with risks of the 10 most common primary cancers through a series of nested case–control studies based on the general population using records from 660 UK general practices within the QResearch Database. Expand
Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort
TLDR
The hypothesis that risk of oesophageal, but not of gastric or colorectal, cancer is increased in users of oral bisphosphonates is examined to argue against methodological problems in the selection of cases and controls or in the analysis. Expand
Esophageal and gastric cancer incidence and mortality in alendronate users
TLDR
The early decrease in esophageal cancer rates may relate to the greater use of endoscopy before starting alendronate, and this could lead to more cancers being diagnosed at a stage when their esphageal or gastric location could be accurately distinguished. Expand
...
1
2
3
4
5
...